Ask an Expert
Bengaluru, once synonymous with India’s IT revolution, is rapidly evolving into the nation’s next powerhouse for pharma and life sciences innovation. The city’s growing concentration of Global Capability Centers (GCCs), coupled with its scientific depth, digital readiness, and entrepreneurial energy, is redefining the way healthcare is researched, developed, and delivered.
From Generics to Innovation-Driven Healthcare
Industry experts, Ishwar Bajaj (Biocon), Dr Sachin Mundade (Micro Labs), and Mayank Garg (Biocon Biologics) have pointed out that India’s strength in generics has built a solid foundation, but the next frontier lies in complex biologics, biosimilars, and specialty drugs. Bengaluru’s ecosystem, with its blend of advanced R&D centers, tech-driven GCCs, and startup innovation, provides the right environment for this evolution.
Dr Goutam Pujari (Apotex Research) and Dr Maloy Ghosh (Zumutor Biologics) highlighted that this shift demands not only scientific rigor but also risk-taking and adaptive collaboration. By merging digital technologies with deep scientific expertise, Bengaluru is poised to deliver scalable, outcome-oriented innovations for the global market.
Ecosystem Synergy: Academia, Startups, and Industry
A defining strength of Bengaluru’s life sciences ecosystem lies in its collaborative fabric. Dr Shailendra Gaur (Cipla) and Loganathan S (Onesource Biopharma) have called out the role of academia & industry partnerships in building a future-ready workforce and translating research into applied innovation.
With Karnataka government’s progressive GCC policy, encouraging apprenticeships, smaller centers, and continuous capability monitoring, the region is nurturing a seamless bridge between education, enterprise, and employment. This synergy is mirrored in the city’s startup culture. Bengaluru’s biotech ventures, often working at the intersection of AI, analytics, and biotechnology, are pushing the boundaries of drug discovery and clinical research. Yet, as several experts noted, the next leap forward depends on stronger access to funding, mentorship, and regulatory clarity to enable these startups to scale sustainably.
Digital Transformation: The New Catalyst
Pharma leaders agree that digital integration is no longer a support function, it is the foundation of competitive advantage. The infusion of AI, automation, data platforms, and advanced analytics into R&D, manufacturing, and compliance processes is enabling real-time decision-making, quality control, and faster time-to-market. According to Elayaraja Natarajan (Lyrus Life Sciences), this convergence of science and digital capability is transforming how global pharma companies operate from their Indian GCCs, making Bengaluru a living lab for innovation-driven, technology-enabled healthcare.
The Road Ahead
As Bengaluru’s GCCs, research institutions, and startups deepen collaboration, the city is moving from being a participant in the global pharma value chain to becoming a creator of it. Continuous learning, cross-industry partnerships, and digital fluency will define its ascent.
If India’s earlier success lay in being the pharmacy of the world, Bengaluru now stands ready to script the next chapter, as the innovation capital of global healthcare.
Source: https://www.expresspharma.in/panel-discussion-bengaluru-an-emerging-global-innovation-gateway/
Share on 
